SCHEMBL16635678

SCHEMBL16635678

O=C(O)C1CCCCC1c1nc(-c2ccc(F)cc2)sc1Br

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSK P43235 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.41
TAAR1 Q96RJ0 1/20 0.39
TBXA2R P21731 1/20 0.38
LMNA P02545 1/20 0.37
PTGDR2 Q9Y5Y4 2/20 0.37
HTT P42858 2/20 0.36
ALDH1A1 P00352 1/20 0.36
TRPV1 Q8NER1 1/20 0.36
ALOX5 P09917 1/20 0.36
NPC1 O15118 2/20 0.36
RAB9A P51151 2/20 0.36
TDP1 Q9NUW8 1/20 0.36
HDAC3 O15379 1/20 0.36
HDAC1 Q13547 1/20 0.36
HDAC2 Q92769 1/20 0.36
HDAC8 Q9BY41 1/20 0.36
HDAC6 Q9UBN7 1/20 0.36
ALOX5AP P20292 1/20 0.35
DGAT1 O75907 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16635827 1.00 CTSK (0.42) CTSKSMN1; SMN2TAAR1TBXA2RLMNA
SCHEMBL16636407 0.86 SLC6A2 (0.45) CTSKALDH1A1TRPV1NPC1RAB9A
SCHEMBL16636408 0.86 SLC6A2 (0.45) CTSKALDH1A1TRPV1NPC1RAB9A
SCHEMBL16635754 0.80 CTSK (0.67) CTSK
SCHEMBL16635861 0.76 SMN1; SMN2 (0.38) CTSKSMN1; SMN2TAAR1TBXA2RHTT
SCHEMBL16635958 0.76 LMNA (0.50) SMN1; SMN2TAAR1TBXA2RLMNAALDH1A1
SCHEMBL16636019 0.74 ALDH1A1 (0.38) SMN1; SMN2HTTALDH1A1TDP1ALOX5AP
SCHEMBL16635762 0.72 FNTA (0.43) SMN1; SMN2ALOX5AP
SCHEMBL16635769 0.70 PIM1 (0.33) PTGDR2
SCHEMBL16635859 0.70 HDAC9 (0.34)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3054947-B1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK SHARP & DOHME (US) 2021-11-17 EP disclosed
US-9573913-B2 Cathepsin cysteine protease inhibitors MERCK SHARP & DOHME CORP. (US) 2017-02-21 US disclosed
US-20160244417-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2016-08-25 US disclosed
EP-3054947-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS Merck Sharp & Dohme Corp. (US) 2016-08-17 EP disclosed
WO-2015054038-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2015-04-16 WO disclosed
WO-2015051479-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2015-04-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160244417-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS CTSB, CTSS, CTSZ CTSK 4/4885SMN1; SMN2 4512/4885TAAR1 4771/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.